Brief: Synact Gets Patent Term Adjustment for Resomelagon Therapy
12/05/2025 13:42
May 12 (Reuters) - SynAct Pharma AB SYNACT.ST: SYNACT RECEIVES ISSUE NOTIFICATION AND PATENT TERM ADJUSTMENT FOR US PATENT COVERING RESOMELAGON (AP1189) COMBINATION THERAPY SYNACT RECEIVES ISSUE NOTIFICATION AND PATENT TERM ADJUSTMENT FOR US PATENT COVERING RESOMELAGON (AP1189) COMBINATION THERAPY Source text: ID:nMFN5kKXXB Further company coverage: SYNACT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development